Dr. Rachel Wellner, founder and CEO of Kalem Diagnostic Solution, Inc., has developed a technology that provides biopsy evaluations in less than 10 minutes with 94-99% accuracy. The technology allows for real-time evaluation of breast cancer while the patient is still on the procedure table. Dr. Wellner’s background as a board-certified breast surgical oncologist and her passion for international health led her to pursue a career in medicine. She later transitioned into the field of entrepreneurship, combining her interests in global health, medicine, and innovation. Dr. Wellner’s team is currently in the prototyping stage and has raised $600,000 in funding. They are seeking additional funding and government grants to further develop their technology. The end goal for the company is a high-value exit or potential IPO, with potential buyers including diagnostics companies and lab companies.